Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 15/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 8/20 | 0.37 |
| ▸ | DUT | P33316 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16154316 | 0.87 | DUT (0.38) | RETKDRPIM1PIM2DUT | |
| SCHEMBL15894530 | 0.84 | RET (0.35) | RETKDRPIM1PIM2DUT | |
| SCHEMBL17077959 | 0.83 | RET (0.41) | RETKDRPIM1PIM2PIM3 | |
| SCHEMBL17464322 | 0.81 | DUT (0.38) | DUT | |
| SCHEMBL15891374 | 0.81 | RET (0.40) | RETKDRPIM1PIM2CSNK2A2 | |
| SCHEMBL30103007 | 0.81 | PIM1 (0.40) | RETKDRPIM1PIM2 | |
| SCHEMBL19269809 | 0.78 | PIM1 (0.41) | RETKDRPIM1PIM2 | |
| SCHEMBL15261632 | 0.78 | PIM1 (0.45) | RETKDRPIM1PIM2CHEK1 | |
| SCHEMBL15261764 | 0.77 | PIM1 (0.44) | RETPIM1PIM2 | |
| SCHEMBL19252601 | 0.76 | PIM1 (0.38) | RETPIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160024114-A1 | MACROCYCLIC RIP2 KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024114-A1 | MACROCYCLIC RIP2 KINASE INHIBITORS | RIPK2, RIPK1, RIPK3 | RET 280/4885KDR 1809/4885PIM1 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.